1972 Nobel Prize in Physiology or Medicine: Edelman and Porter Unravel the Structure of Antibody Molecules

What You'll Learn in This Article

You will understand how Edelman and Porter solved the fundamental mystery of why antibodies can have infinite diversity while still functioning in a standardized manner by isolating a single antibody from a patient with multiple myeloma and comparing its amino acid sequences. You will also learn why this discovery became the theoretical foundation for today's antibody drugs and immunological diagnostics.

A Story That Goes Against Common Sense: How Can a Single Molecule Have Infinite Diversity?

Let's begin with the basic structure of an antibody. An antibody molecule is a protein composed of four polypeptide chains. Two of these are identical long chains of approximately 450 amino acids — the heavy chains (H chains) — and the other two are identical short chains of approximately 210 amino acids — the light chains (L chains). These two types of chains are held together by disulfide bonds (S-S bonds) to form the basic H2L2 scaffold, and the H chains carry a small amount of attached carbohydrate.

Why this structure is remarkable becomes clearer alongside the following fact. Our bodies are constantly bombarded with foreign substances — pathogens and other non-self material — and every time, the immune system must produce antibodies that fight those foreign substances.

The Critical Mystery: The types of foreign substances (antigens) that our body can encounter are virtually infinite—not only known pathogens, toxins, and foreign substances, but also completely new ones. How can our bodies create antibodies that bind specifically to foreign substances it has never seen before? It's like a key maker creating a key without seeing the lock, and it turns out to fit perfectly.

To solve this mystery, it was first necessary to accurately understand how the antibody molecule itself is structured. Edelman and Porter revealed this structure.

In the language of computer science, this problem is a protocol design issue where the interface is standardized, but the payload maintains diversity. The system cannot know in advance all the data it will receive, but the interface that processes that data must be standardized.

The Context of the Time: Détente in the Cold War and the Korean Yushin System

1972 was a year when the international Cold War was easing, but Korea was strengthening its authoritarianism.

In world history: February 21-28, Nixon's visit to China - the first official visit by a U.S. president to China. The Shanghai Communiqué was released, heralding the normalization of Sino-American relations. This was a moment when the bipolarity of the Cold War was fundamentally being reshaped. June: the Watergate Hotel break-in - the beginning of Nixon's resignation two years later. September: at the Munich Olympics, the Palestinian armed group "Black September" took Israeli athletes hostage, resulting in 11 deaths. February: Sapporo Winter Olympics - the first Winter Olympics in Asia.

In Korean history: July 4, the July 4th North-South Joint Statement - North and South Korea agreed on the three principles of independence, peace, and national unity. This became a milestone for future North-South dialogue. October 17, President Park Chung-hee's declaration of the October Yushin - dissolution of the National Assembly, suspension of the constitution, and enactment of the Yushin Constitution. This marked the beginning of the seven-year Yushin regime, a pivotal turning point in Korean politics.

In this tumultuous year, the Nobel Committee recognized the elucidation of the antibody structure. At a time when international politics was reshaping the boundaries between self and other, the structure of antibodies, which distinguish self from other within the body, was revealed.

The Two Laureates: Rockefeller and Oxford

Gerald M. Edelman (1929- ) is an American biochemist. He studied at the University of Pennsylvania School of Medicine (medical degree, 1954), and then served for two years in the medical corps in Paris before moving to Rockefeller University in New York in 1957 and earning his Ph.D. there in 1960, at which point he was appointed a professor. Before antibodies, he had at one point been interested in DNA replication.

After receiving his Ph.D. from Rockefeller University (1960), he served as a professor at Rockefeller University (1963-1992) for 30 years. From 1992, he became the director of the Scripps Research Institute. In his later years, his interests shifted from antibody research to brain theory (Neural Darwinism).

Rodney R. Porter (1917-1985) was a British biochemist. Born in Liverpool, England, in 1917, he received his master's degree from the University of Liverpool in 1939, and then served in World War II from 1940 to 1946. After the war he returned to Cambridge and earned his Ph.D. under Sanger (Frederick Sanger, two-time Nobel laureate in Chemistry in 1958 and 1980), subsequently working at the Royal Medical Research Institute in Mill Hill from 1949 to 1960. He then held a professorship in immunology at St Mary's Hospital in London (1960-1967) before moving to a chair in biochemistry at Oxford in 1967 — until his life ended abruptly in an accident in 1985.

Porter's crucial training was being mentored by Sanger (the originator of protein and DNA sequence determination, a two-time Nobel laureate). The sequence and structure analysis methods he learned from his mentor were applied to antibody research. In fact, he drew on the work of the Austrian-American immunologist Landsteiner (Karl Landsteiner, 1930 Nobel laureate in Physiology or Medicine) as a reference, and pursued the biological functions of antibodies grounded in their structure. He also worked on the assembly principle of the chains that make up antibody molecules, and on the interaction between antigen-antibody complexes and the complement system, another key immune protein circulating in the blood.

The Decisive Discovery: Separation of the Variable and Constant Regions

The two researchers elucidated the antibody structure using different approaches.

Edelman's approach: Sequence comparison. Edelman and a handful of other immunologists isolated various types of single antibody molecule from the serum of patients with multiple myeloma and compared each antibody's primary structure (amino acid sequence). The result was decisive: for each antibody the N-terminal roughly one-quarter of the H chain and the N-terminal half of the L chain had different amino acid sequences, while, by contrast, the C-terminal roughly three-quarters of the H chain and the C-terminal half of the L chain were almost identical across antibodies. These two regions were subsequently named the variable region (V) and the constant region (C).

Multiple myeloma is important because this disease is characterized by the abnormal proliferation of a specific B-cell clone, which mass-produces a single type of antibody. In normal serum, hundreds of thousands of different antibodies are mixed, making sequence analysis impossible, but in the serum of myeloma patients, a pure sample of a single antibody can be obtained. By isolating different myeloma antibodies from different patients and comparing their sequences, they discovered which region differed and which region was the same.

The crucial observation: One end of the antibody (the N-terminal region) has a different sequence for each patient, while the other end (the C-terminal region) is almost the same.

Porter's approach: Cleavage experiment. Porter used papain (a protein-degrading enzyme extracted from papaya) to cleave antibodies into two fragments.

• Fab fragment (Fragment antigen-binding): The part that binds to the antigen. Responsible for the different specificities of each antibody. Contains the variable region.
• Fc fragment (Fragment crystallizable): The part that crystallizes well (hence, crystallizable). Almost the same for all antibodies. Contains the constant region.

When Porter first discovered the Fc fragment, its biological function was still an open question. Later measurements clarified that this Fc fragment directly interacts with immune cells such as macrophages and triggers a range of other immune responses — a decisive mediator role.

The results of the two researchers combined to create a complete picture of the antibody structure.

• Y-shaped antibody: Four chains (H2L2) are connected by disulfide bonds to form a Y shape.
• The two ends of the Y (Fab) = variable region = antigen-binding site. Responsible for the different specificities of each antibody.
• The root of the Y (Fc) = constant region = interaction site with immune cells and the complement system. Used identically by all antibodies.

The Five Types of Antibodies and Their Roles

The impact of this discovery can be summarized as follows. Humans possess five types of antibody — IgM, IgD, IgG, IgA, and IgE — of which most circulating antibodies are IgG, and the ones responsible for allergic reactions are IgE. Beyond mapping this catalog, the structural elucidation laid the crucial groundwork for Susumu Tonegawa's later (1987 Nobel Prize) discovery of how the genetic mechanism generates antibody diversity.

• IgG: The most abundant antibody in the blood. The main defense against infection.
• IgM: Early response to infection. Exists in a form where five units are bound together.
• IgA: Defends the mucous membranes (digestive tract and respiratory tract). Also contained in breast milk.
• IgE: Response to allergies and parasitic infections.
• IgD: Function was unclear for a long time, but now known to play a role in signal transduction on the surface of B cells.

All five types share the basic structure of variable region + constant region, but differ in the Fc region, allowing them to interact with different immune cells. The interface is the same, but the execution context is different.

The genetic mechanism of how the infinite diversity of the variable region is created was later elucidated by Susumu Tonegawa (1987 Nobel Prize). The key to his discovery is that V, D, and J gene fragments are randomly recombined, creating virtually infinite combinations of variable regions. The elucidation of the antibody structure by Edelman and Porter provided the theoretical foundation for this genetic mechanism to be discovered.

Interface-Payload Separation Architecture — CS Framework

Now, let's summarize the CS implications of antibody structure.

In protocol design, separating the interface from the payload is a fundamental principle. In HTTP, the header contains a standardized interface (method, status code, content type), while the body contains application-specific payloads. This separation allows for:

• The infrastructure layer doesn't need to know the payload: Load balancers, CDNs, and proxies can understand only the HTTP header and forward the body as is.
• Applications can freely design payloads on top of a standard interface: In any format, such as JSON, XML, or binary.

Antibodies are exactly this architecture.

• Fc = Standard Interface: Responsible for standard interactions such as binding to immune cells, complement, and crossing the placenta. Immune cells only need to recognize the Fc to know what type of antigen the antibody targets.
• Fab = Diverse Payload: Each antibody has different antigen specificity. This allows for infinite diversity.

The power of this separation: If the entire antibody had a completely different structure for each antigen, immune cells would have to evolve different receptors for each antigen type. However, with a standardized Fc, immune cells can respond to infinite antigen types with only a few Fc receptors.

Direct correspondence with software design principles: Dependency Inversion Principle - The principle that high-level modules should not depend on low-level modules, but rather on abstractions. The Fc of the immune system = abstract interface. Fab = concrete implementation. Even when a new antigen (concrete implementation) appears, the immune system (high-level module) does not need to be modified.

Genetic diversity generation in the variable region = compile-time code generation. Each B cell randomly combines V, D, and J segments to determine the sequence of the variable region of its antibody — the individual generates its own code during its lifetime. This approach, discovered by evolution, uses a principle similar to the randomized initialization in artificial neural networks.

Limitations of the analogy: Of course, the antibody system is much more probabilistic than software. Several probabilistic processes, such as random combination, clonal selection, and antigen maturation, are involved. However, the fundamental principle of "standard interface + diverse payload" is exactly the same.

The Legacy That Continues Today

The discovery of the antibody structure by Edelman and Porter continues to live on in various forms today.

• Monoclonal antibody drugs: Rituximab (lymphoma), trastuzumab (HER2-positive breast cancer), adalimumab (rheumatoid arthritis), nivolumab (immune checkpoint inhibitor), etc. Today, antibody drugs are used as targeted therapies for various diseases. As of 2020, most of the top 10 best-selling drugs in the world are antibody drugs.
• Immune diagnostics: ELISA, Western blotting, immunohistochemistry, and other antibody-based diagnostic techniques are standard tools in clinical and research settings. COVID-19 antigen tests also use this principle.
• CAR-T cell therapy: A therapy that genetically modifies T cells to express the antigen-binding region (scFv) of a specific antibody, causing them to attack specific cancer cells. It has dramatic effects on acute lymphoblastic leukemia, etc.
• Bispecific antibodies: Artificial antibodies that recognize two different antigens simultaneously. Blinatumomab (leukemia), etc. This is a technology that manipulates the specificity of Fab.
• Understanding autoimmune diseases: Antibodies that react to self-antigens are the cause of autoimmune diseases. This understanding makes targeted therapy possible.

Why It Matters

What the two men left behind is an empirical demonstration of the principle that "even complex diversity can be managed through the standardization of fundamental architectures."

In a situation where the types of foreign substances encountered by the body are virtually infinite, if a completely different defense system were needed for each foreign substance, immunity would be impossible to evolve. The architecture of a standardized framework (Fc) + diverse recognition sites (Fab) solved this problem. This principle is the biological demonstration of the perspective we take for granted today — "scalable systems are built on standard interfaces with diversity layered on top."

This discovery led to Tonegawa's discovery of genetic recombination (1987) 15 years later, and then to immune checkpoint inhibitors (2018) 30 years later. The discovery of the antibody structure was a crucial first step that opened up half a century of immunology and oncology research.

The special narrative of this award is that Porter, who was trained under a mentor who was an expert in sequence analysis, made the discovery. As noted above, he was trained under the guidance of Sanger (the founder of protein and DNA sequencing) and revealed the exact amino acid structure of the antibody. It is an example of an academic lineage in which the mentor's methodology is applied by the student to a different subject, leading to a new discovery.

1972 Edelman & Porter Summary: Discovery of the separation of the variable region (V, antigen-binding) and the constant region (C, interaction with immune cells) of the antibody molecule (H2L2). Edelman approached this by comparing the sequences of single antibodies from patients with multiple myeloma, and Porter by papain cleavage. Establishment of a Y-shaped interface-payload separation architecture. The theoretical root of today's antibody drugs, immune diagnostics, and CAR-T therapy.

← Previous: 1971 — Sutherland → Next: 1973 — Frisch, Lorenz, and Tinbergen